Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38

Cancer Biology and Therapy

Volumn 7, Issue 6, 2008, Pages 822-832

  Gongora, Céline ^a,c   Candeil, Laurent ^a   Vezzio, Nadia ^a,c   Copois, Virginie ^a   Denis, Vincent ^a,c   Breil, Corinne ^a   Molina, Franck ^a   Fraslon, Caroline ^b   Conseiller, Emmanuel ^b   Pau, Bernard ^a   Martineau, Pierre ^a,c   Del Rio, Maguy ^a,c,d  

^a CNRS   (France)

^b Département d'Oncologie   (France)

^c UNIV MONTPELLIER   (France)

^d INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

Author keywords

Colorectal cancer; Drug resistance; Microarray; SN38

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; DNA TOPOISOMERASE; STAT1 PROTEIN; STAT3 PROTEIN; STAUROSPORINE; SYNAPTOPHYSIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; INTERFERON; IRINOTECAN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE; CELL PROLIFERATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN GENOME; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; UNINDEXED SEQUENCE; APOPTOSIS; CELL SURVIVAL; COLON TUMOR; DNA MICROARRAY; DRUG RESISTANCE; IC 50; METABOLISM; PATHOLOGY; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITORY CONCENTRATION 50; INTERFERONS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TIME FACTORS;

EID: 46749154607     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.6.5838     Document Type: Article

References (49)

1. Rougier P, Mitry E. Colorectal cancer chemotherapy: irinotecan. Semin Oncol 2000; 27:138-43.
2. Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 1997; 25:1157-64.
3. Gupta M, Fujimori A, Pommier Y. Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1995; 1262:1-14.
4. Pommier Y, Pourquier P, Fan Y, Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998; 1400:83-105.
5. Chen ZS, Furukawa T, Sumizawa T, et al. ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol 1999; 55:921-8.
6. Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E, Chen YC. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem Pharmacol 2000; 60:831-7.
7. Kawabata S, Oka M, Shiozawa K, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 2001; 280:1216-23.
8. Candeil L, Gourdier I, Peyron D, et al. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int J Cancer 2004; 109:848-54.
9. van Ark-Otte J, Kedde MA, van der Vijgh WJ, et al. Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br J Cancer 1998; 77:2171-6.
10. Takahashi T, Fujiwara Y, Yamakido M, Katoh O, Watanabe H, Mackenzie PI. The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro. Jpn J Cancer Res 1997; 88:1211-7.
11. Sugimoto Y, Tsukahara S, Oh-hara T, Isoe T, Tsuruo T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 1990; 50:6925-30.
12. Woessner RD, Eng WK, Hofmann GA, et al. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol Res 1992; 4:481-8.
13. Chang JY, Liu JF, Juang SH, Liu TW, Chen LT. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Cancer Res 2002; 62:3716-21.
14. Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res 1995; 55:1339-46.
15. Urasaki Y, Laco GS, Pourquier P, et al. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res 2001; 61:1964-9.
16. Wang LF, Ting CY, Lo CK, et al. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. Cancer Res 1997; 57:1516-22.
17. Pommier Y, Redon C, Rao VA, et al. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res 2003; 532:173-203.
18. Park SY, Lam W, Cheng YC. X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res 2002; 62:459-65.
19. Nieves Neira W, Pommier Y. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. Int J Cancer 1999; 82:396-404.
20. Waf1/Cip1 acts in synergy with bcl-2 to confer multidrug resistance in a camptothecin-selected human lung-cancer cell line. Int J Cancer 1999; 83:790-7.
21. Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999; 65:576-82.
22. Khanna R, Morton CL, Danks MK, Potter PM. Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res 2000; 60:4725-8.
23. Yu J, Shannon WD, Watson MA, McLeod HL. Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res 2005; 11:2053-62.
24. Soret J, Gabut M, Dupon C, et al. Altered serine/arginine-rich protein phosphorylation and exonic enhancer-dependent splicing in Mammalian cells lacking topoisomerase I. Cancer Res 2003; 63:8203-11.
25. Liu LF, Miller KG. Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc Natl Acad Sci USA 1981; 78:3487-91.
26. Platanias LC. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol Ther 2003; 98:129-42.
27. Cummings J, Zelcer N, Allen JD, et al. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochem Pharmacol 2004; 67:31-9.
28. Pommier Y, Pourquier P, Urasaki Y, Wu J, Laco GS. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat 1999; 2:307-318.
29. Saeki T, Stromberg K, Qi CF, et al. Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors. Cancer Res 1992; 52:3467-73.
30. Normanno N, Selvam MP, Bianco C, et al. Amphiregulin anti-sense oligodeoxynucleotides inhibit growth and transformation of a human colon carcinoma cell line. Int J Cancer 1995; 62:762-6.
31. Mishra R, Leahy P, Simonson MS. Gene expression profiling reveals role for EGF-family ligands in mesangial cell proliferation. Am J Physiol Renal Physiol 2002; 283:1151-9.
32. Lasorella A, Boldrini R, Dominici C, et al. Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res 2002; 62:301-6.
33. Murata K, Sudo T, Kameyama M, et al. Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility. Clin Exp Metastasis 2000; 18:599-604.
34. Ogawa R, Streiff MB, Bugayenko A, Kato GJ. Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53 and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells. Blood 2002; 99:3390-7.
35. Fujita M, Furukawa Y, Tsunoda T, Tanaka T, Ogawa M, Nakamura Y. Upregulation of the ectodermal-neural cortex 1 (ENC1) gene, a downstream target of the beta-catenin/T-cell factor complex, in colorectal carcinomas. Cancer Res 2001; 61:7722-6.
36. Katoh Y, Katoh M. Canonical WNT signaling pathway and human AREG. Int J Mol Med 2006; 17:1163-6.
37. Zhao DH, Hong JJ, Guo SY, et al. Aberrant expression and function of TCF4 in the proliferation of hepatocellular carcinoma cell line BEL-7402. Cell Res 2004; 14:74-80.
38. Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, Sage EH. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest 2003; 111:487-95.
39. Schiemann BJ, Neil JR, Schiemann WP. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell 2003; 14:3977-88.
40. Tai IT, Dai M, Owen DA, Chen LB. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest 2005; 115:1492-502.
41. Wosikowski K, Silverman JA, Bishop P, Mendelsohn J, Bates SE. Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells. Biochim Biophys Acta 2000; 1497:215-26.
42. Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4:263-75.
43. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5:375-86.
44. Kato Y, Lewalle JM, Baba Y, et al. Induction of SPARC by VEGF in human vascular endothelial cells. Biochem Biophys Res Commun 2001; 287:422-6.
45. Engelman JA, Lisanti MP, Scherer PE. Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesis. J Biol Chem 1998; 273:32111-20.
46. Ziegler Heitbrock HW, Blumenstein M, Kafferlein E, et al. In vitro desensitization to lipopolysaccharide suppresses tumour necrosis factor, interleukin-1 and interleukin-6 gene expression in a similar fashion. Immunology 1992; 75:264-8.
47. Deacon K, Mistry P, Chernoff J, Blank JL, Patel R. p38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest. Mol Biol Cell 2003; 14:2071-87.
48. Losa JH, Parada Cobo C, Viniegra JG, Sanchez Arevalo Lobo VJ, Ramon y Cajal S, Sanchez Prieto R. Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 2003; 22:3998-4006.
49. Engelberg D. Stress-activated protein kinases-tumor suppressors or tumor initiators? Semin Cancer Biol 2004; 14:271-82.